These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 12010505)
1. Sequential analysis of hepatitis B virus core promoter and precore regions in cancer survivor patients with chronic hepatitis B before, during and after interferon treatment. Zampino R; Marrone A; Cirillo G; del Giudice EM; Utili R; Karayiannis P; Liang TJ; Ruggiero G J Viral Hepat; 2002 May; 9(3):183-8. PubMed ID: 12010505 [TBL] [Abstract][Full Text] [Related]
2. Low HBeAg serum levels correlate with the presence of the double A1762T/G1764A core promoter mutation and a positive response to interferon in patients with chronic hepatitis B virus infection. Marrone A; Zampino R; Luongo G; Utili R; Karayiannis P; Ruggiero G Intervirology; 2003; 46(4):222-6. PubMed ID: 12931030 [TBL] [Abstract][Full Text] [Related]
3. Core promoter mutations 3 years after anti-hepatitis B e seroconversion in patients with chronic hepatitis B or hepatitis B and C infection and cancer remission. Zampino R; Marrone A; Karayiannis P; Cirillo G; del Giudice EM; Rania G; Utili R; Ruggiero G Am J Gastroenterol; 2002 Sep; 97(9):2426-31. PubMed ID: 12358268 [TBL] [Abstract][Full Text] [Related]
4. Effects of interferon alpha therapy on the catalytic domains of the polymerase gene and basal core promoter, precore and core regions of hepatitis B virus. Chen RY; Bowden S; Desmond PV; Dean J; Locarnini SA J Gastroenterol Hepatol; 2003 Jun; 18(6):630-7. PubMed ID: 12753143 [TBL] [Abstract][Full Text] [Related]
5. Nucleotide divergences in the core promoter and precore region of genotype D hepatitis B virus in patients with persistently elevated or normal ALT levels. Bozdayi AM; Bozkaya H; Türkyilmaz AR; Sarýodlu M; Cetinkaya H; Karayalçin S; Yurdaydin C; Uzunalimoğlu O J Clin Virol; 2001 Apr; 21(1):91-101. PubMed ID: 11255102 [TBL] [Abstract][Full Text] [Related]
6. Distinct evolution and predictive value of hepatitis B virus precore and basal core promoter mutations in interferon-induced hepatitis B e antigen seroconversion. Yang HC; Chen CL; Shen YC; Peng CY; Liu CJ; Tseng TC; Su TH; Chuang WL; Yu ML; Dai CY; Liu CH; Chen PJ; Chen DS; Kao JH Hepatology; 2013 Mar; 57(3):934-43. PubMed ID: 23112104 [TBL] [Abstract][Full Text] [Related]
7. Genetic heterogeneity of the precore and the core promoter region of genotype C hepatitis B virus during lamivudine therapy. Kuwahara R; Kumashiro R; Murashima S; Ogata K; Tanaka K; Hisamochi A; Hino T; Ide T; Tanaka E; Koga Y; Sata M J Med Virol; 2004 Jan; 72(1):26-34. PubMed ID: 14635007 [TBL] [Abstract][Full Text] [Related]
8. Effect of host and viral factors on hepatitis B e antigen-positive chronic hepatitis B patients receiving pegylated interferon-α-2a therapy. Tseng TC; Yu ML; Liu CJ; Lin CL; Huang YW; Hsu CS; Liu CH; Kuo SF; Pan CJ; Yang SS; Su CW; Chen PJ; Chen DS; Kao JH Antivir Ther; 2011; 16(5):629-37. PubMed ID: 21817184 [TBL] [Abstract][Full Text] [Related]
9. Association of characteristics of HBV quasispecies with hepatitis B surface antigen seroconversion after pegylated interferon-α-2a treatment in child patients. Yang J; Yang G; He H; Ning L; Liu Z; Fu Q; Chen H; Deng H; Wang Z; Luo K Antivir Ther; 2018; 23(7):567-574. PubMed ID: 30095435 [TBL] [Abstract][Full Text] [Related]
10. [The prevalence and clinical significance of precore and core promoter mutations in Korean patients with chronic hepatitis B virus infection]. Kim HJ; Yoo BC Taehan Kan Hakhoe Chi; 2002 Jun; 8(2):149-56. PubMed ID: 12499800 [TBL] [Abstract][Full Text] [Related]
11. Mutation Changes in the preC/Core Promoter in HBeAg-Positive Patients With Chronic Hepatitis B During Interferon Therapy. Geng Y; Wang X; Lu X; Wu X; Xu N; Han L; Xu J Medicine (Baltimore); 2016 Feb; 95(5):e2657. PubMed ID: 26844490 [TBL] [Abstract][Full Text] [Related]
12. Genomic variations in precore and cytotoxic T lymphocyte regions in chronic hepatitis B in relationship to interferon responsiveness. Shindo M; Okuno T Liver; 2000 Apr; 20(2):136-42. PubMed ID: 10847482 [TBL] [Abstract][Full Text] [Related]
13. Hepatitis B virus basal core promoter/precore mutants and association with liver cirrhosis in children with chronic hepatitis B virus infection. Zhong YW; Di FL; Liu C; Zhang XC; Bi JF; Li YL; Wu SQ; Dong H; Liu LM; He J; Shi YM; Zhang HF; Zhang M Clin Microbiol Infect; 2016 Apr; 22(4):379.e1-379.e8. PubMed ID: 26577140 [TBL] [Abstract][Full Text] [Related]
14. The clinical significance of core promoter and precore mutations during the natural course and interferon therapy in patients with chronic hepatitis B. Shindo M; Hamada K; Koya S; Sokawa Y; Okuno T Am J Gastroenterol; 1999 Aug; 94(8):2237-45. PubMed ID: 10445556 [TBL] [Abstract][Full Text] [Related]
15. Mutations of pre-core and basal core promoter before and after hepatitis B e antigen seroconversion. Kamijo N; Matsumoto A; Umemura T; Shibata S; Ichikawa Y; Kimura T; Komatsu M; Tanaka E World J Gastroenterol; 2015 Jan; 21(2):541-8. PubMed ID: 25593470 [TBL] [Abstract][Full Text] [Related]
16. [Clinical efficacy of various antiviral-based strategies to treat chronic hepatitis patients with positivity for hepatitis B e antigen and rtN236T mutation]. Yue W; Yuan H; Mao XR; Deng YD; Chen L Zhonghua Gan Zang Bing Za Zhi; 2013 Mar; 21(3):184-8. PubMed ID: 23967738 [TBL] [Abstract][Full Text] [Related]
17. Different hepatitis B virus genotypes are associated with different mutations in the core promoter and precore regions during hepatitis B e antigen seroconversion. Chan HL; Hussain M; Lok AS Hepatology; 1999 Mar; 29(3):976-84. PubMed ID: 10051506 [TBL] [Abstract][Full Text] [Related]
18. High level of hepatitis B virus DNA after HBeAg-to-anti-HBe seroconversion is related to coexistence of mutations in its precore and basal core promoter. Peng XM; Huang GM; Li JG; Huang YS; Mei YY; Gao ZL World J Gastroenterol; 2005 May; 11(20):3131-4. PubMed ID: 15918203 [TBL] [Abstract][Full Text] [Related]
19. Next generation sequencing identifies baseline viral mutants associated with treatment response to pegylated interferon in HBeAg-positive chronic hepatitis B. Chuaypen N; Payungporn S; Poovorawan K; Chotiyaputta W; Piratvisuth T; Tangkijvanich P Virus Genes; 2019 Oct; 55(5):610-618. PubMed ID: 31359359 [TBL] [Abstract][Full Text] [Related]
20. Hepatitis B virus DNA quantitation and detection of core promoter, precore and polymerase mutations in chronic hepatitis B: evaluation and clinical usefulness of three new commercial assays. Zampino R; Marrone A; Finnström N; Eriksson T; Törmänen V; Hedrum A; Attanasio V; Rosario P; Utili R; Ruggiero G Infez Med; 2005 Jun; 13(2):86-96. PubMed ID: 16220028 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]